Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Mol Med Rep. 2021 Dec;24(6). doi: 10.3892/mmr.2021.12486. Epub 2021 Oct 13.
Glioma is a primary cerebral neoplasm that originates from glial tissue and spreads to the central nervous system. Long noncoding RNAs are known to play a role in glioma cells by regulating cell proliferation, migration and invasion. The aim of the present study was to investigate the mechanism by which long intergenic non‑protein coding RNA (LINC) 01138 affects glycolysis and proliferation in glioma cells via the microRNA (miR)‑375/specificity protein 1 (SP1) axis. LINC01138 expression was assessed in glioma tissues and cells using reverse transcription‑quantitative PCR and the association between LINC01138 and patient clinicopathological features was analyzed. Glucose uptake, lactic acid secretion, cell proliferation, and glycolysis‑related enzyme levels were detected following LINC01138 silencing using CCK‑8, EDU assay and western blot analysis. miR‑375 and SP1 expression levels were also assessed, and the distribution of LINC01138 in the nucleus and cytoplasm was investigated using subcellular fractionation localization. Furthermore, the binding relationships between LINC01138 and miR‑375, and between miR‑375 and SP1 were assessed via dual‑luciferase experiment, RIP and RNA pull‑down assays. Finally, xenograft transplantation models were used to verify the results. LINC01138 was highly expressed in glioma, which was independent of patient sex or age but was significantly related to tumor diameter, the World Health Organization tumor grade and lymph node metastasis. Silencing LINC01138 significantly reduced glioma glycolysis and cell proliferation. Moreover, LINC01138 acted as a competing endogenous RNA to sponge miR‑375 and promote SP1 expression. miR‑375 inhibition significantly reversed the effect of LINC01138 silencing. In addition, silencing LINC01138 significantly reduced tumor growth . The present study demonstrated that silencing LINC01138 inhibited aerobic glycolysis and thus reduced glioma cell proliferation, potentially by modulating the miR‑375/SP1 axis.
神经胶质瘤是一种源自神经胶质组织并扩散至中枢神经系统的原发性脑肿瘤。长链非编码 RNA 已被证实可通过调节细胞增殖、迁移和侵袭来影响神经胶质瘤细胞。本研究旨在探讨长链非编码 RNA(lncRNA)01138 通过 microRNA(miR)-375/特异性蛋白 1(SP1)轴影响神经胶质瘤细胞糖酵解和增殖的机制。采用逆转录定量 PCR 检测神经胶质瘤组织和细胞中 LINC01138 的表达,并分析 LINC01138 与患者临床病理特征的相关性。采用 CCK-8、EDU 检测和 Western blot 分析沉默 LINC01138 后葡萄糖摄取、乳酸分泌、细胞增殖和糖酵解相关酶水平。还评估了 miR-375 和 SP1 的表达水平,并通过亚细胞分离定位检测 LINC01138 在核和细胞质中的分布。此外,通过双荧光素酶实验、RIP 和 RNA 下拉实验评估 LINC01138 与 miR-375 之间以及 miR-375 与 SP1 之间的结合关系。最后,使用异种移植移植模型验证结果。LINC01138 在神经胶质瘤中高表达,与患者性别或年龄无关,但与肿瘤直径、世界卫生组织肿瘤分级和淋巴结转移显著相关。沉默 LINC01138 可显著降低神经胶质瘤的糖酵解和细胞增殖。此外,LINC01138 作为竞争内源性 RNA 可与 miR-375 结合并促进 SP1 表达。miR-375 抑制可显著逆转 LINC01138 沉默的作用。此外,沉默 LINC01138 可显著降低肿瘤生长。本研究表明,沉默 LINC01138 可抑制有氧糖酵解,从而降低神经胶质瘤细胞增殖,可能通过调节 miR-375/SP1 轴。